The Senate Finance Committee released a bipartisan draft legislation on Friday morning that would give Medicare bonuses to ...

The Federal Trade Commission has extended its antitrust review of Novo Holdings’ $16.5 billion purchase of Catalent by potentially another 30 days as it requests additional information. Both the ...

AstraZeneca is working on moving its BTK inhibitor Calquence into earlier stages of mantle cell lymphoma, releasing what it ...

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) The fight to dom­i­nate the mar­ket for weight loss shots has nev­er been hot­ter, but drug­mak­ers ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

AEON Bio­phar­ma said its bot­u­linum tox­in treat­ment can­di­date failed a Phase 2 mi­graine study at the planned in­ter­im analy­sis. The com­pa­ny ...

Sarepta Therapeutics’ chief scientist suggested that the FDA was ahead of schedule in reviewing the company’s application to ...

Newly appointed CEO Joe Papa outlined his vision for Emergent BioSolutions, which includes winding down two facilities and ...

Jang-Ho Cha had no interest in leaving his post at Novartis, where he led translational medicine for the pharma giant’s work ...

Bristol Myers Squibb will give back a preclinical cancer drug to Schrödinger, returning the SOS1 inhibitor that was part of a ...

Moderna’s shift to a more “restrained” posture was on full display Thursday morning during its first-quarter earnings update.

GSK wants to present Blenrep to regulatory bodies sooner. The UK pharma will submit Blenrep in second-line multiple myeloma ...